ReviewEpilepsy & behavior : E&B2019
Epilepsy, depression, and growth hormone.
Review in Epilepsy & behavior : E&B, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Topiramate and other kainate receptor antagonists for depression: A systematic review of randomized controlled trials.Neuropsychopharmacology reports · 2022Pooled it
- Changes in Multiple microRNA Levels with Antidepressant Treatment Are Associated with Remission and Interact with Key Pathways: A Comprehensive microRNA Analysis.International journal of molecular sciences · 2023Trial
- Growth Hormone and IGF-1 Actions in the Brain and Neuropsychiatric Diseases.Physiology (Bethesda, Md.) · 2026Review
- Risk factor analysis and establishment of a predictive model for epilepsy comorbid with depression.PloS one · 2025Article
- Bibliometric analysis of research in epilepsy and comorbid depression from 2014 to 2023.World journal of psychiatry · 2024Article
- Frontiers and hotspots in comorbid epilepsy and depression: a bibliometric analysis from 2003 to 2023.Frontiers in neurology · 2024Article
- Case report: Epilepsy during the use of recombinant human growth hormone: a report on two cases and a literature review.Frontiers in pharmacology · 2024Article
- Epilepsy and Issues Related to Reproductive Health.Cureus · 2023Review
- Growth hormone proteoformics atlas created to promote predictive, preventive, and personalized approach in overall management of pituitary neuroendocrine tumors.The EPMA journal · 2023Review
- Kullback-Leibler Divergence of Sleep-Wake Patterns Related with Depressive Severity in Patients with Epilepsy.Brain sciences · 2023Article
- Design, Synthesis, and Pharmacology of New Triazole-Containing Quinolinones as CNS Active Agents.Molecules (Basel, Switzerland) · 2023Article
- Cerebrospinal fluid proteomic study of two bipolar disorder cohorts.Molecular psychiatry · 2022Article
- Relationship between chronotype and depressive symptoms among newly hired hospital nurses in the Republic of Korea.Annals of occupational and environmental medicine · 2022Article
- Psychosocial Factors and Psychological Characteristics of Personality of Patients with Chronic Diseases Using Artificial Intelligence Data Mining Technology and Wireless Network Cloud Service Platform.Computational intelligence and neuroscience · 2022Article
- Effect of cognitive behavioral intervention on anxiety, depression, and quality of life in patients with epilepsy.American journal of translational research · 2022Article
- Depression in polycystic ovary syndrome: Focusing on pathogenesis and treatment.Frontiers in psychiatry · 2022Review
- Myocardial Infarction Is Associated With Increased Stroke Severity, In-Hospital Mortality, and Complications: Insights From China Stroke Center Alliance Registries.Journal of the American Heart Association · 2021Article
- Cell Proliferation in the Piriform Cortex of Rats with Motor Cortex Ablation Treated with Growth Hormone and Rehabilitation.International journal of molecular sciences · 2021Article
- The Complex Molecular Picture of Gut and Oral Microbiota-Brain-Depression System: What We Know and What We Need to Know.Frontiers in psychiatry · 2021Review
- The Role of Growth Hormone in Depression: A Human Model.Frontiers in neuroscience · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
Depression affects a large proportion of patients with epilepsy, and is likely due in part to biological mechanism. Hormonal dysregulation due to the disruptive effects of seizures and interictal epileptiform discharges on the hypothalamic-pituitary-adrenal axis likely contributes to high rates of depression in epilepsy. This paper reviews the largely unexplored role of neuroendocrine factors in epilepsy-related depression, focusing on Growth Hormone (GH). While GH deficiency is traditionally considered a childhood disorder manifested by impaired skeletal growth, GH deficiency in adulthood is now recognized as a serious disorder characterized by impairments in multiple domains including mood and quality of life. Could high rates of depression in patients with epilepsy relate to subtle GH deficiency? Because GH replacement therapy has been shown to improve mood and quality of life in patients with GH deficiency, this emerging area may hold promise for patients suffering from epilepsy-related depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.